Hints and tips:
...Pfizer and BioNTech will secure 58 per cent of this year’s $64bn Covid-19 vaccine market, says analytics group Airfinity. But what about the also-rans?...
...BioNTech, which was the first EU company to proceed to clinical trials of its coronavirus vaccine, has also attracted investment from Singapore....
...Officials close to the European negotiations said in September a deal with the bloc had been put on ice because of a glut of vaccines, with the EU having secured up to a total of 2.1bn doses of the Moderna and BioNTech...
...Pfizer, which shares profits on sales of the Covid shot with BioNTech, reports its pre-tax Covid vaccine profit margins are “in the high 20 per cent range”....
...Valneva uses a whole inactivated virus, a more traditional approach than in the approved shots from Oxford/AstraZeneca, BioNTech/Pfizer and Moderna, which all focus on eliciting immune responses to the spike...
...Shortfalls in supply of vaccines to the EU have led to tensions between the UK and the EU over importing shots and raw materials for the current approved jabs from Oxford/AstraZeneca and BioNTech/Pfizer....
...Share prices of the most affected companies rocketed after results from the successful trial of a Pfizer/BioNTech vaccine: equity in IAG, the parent company of British Airways, rose by more than a fifth...
...“I am not against vaccinations per se, but these have been rushed through.”...
International Edition